MIXED PHENOTYPE ACUTE LEUKEMIA
Clinical trials for MIXED PHENOTYPE ACUTE LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new MIXED PHENOTYPE ACUTE LEUKEMIA trials appear
Sign up with your email to follow new studies for MIXED PHENOTYPE ACUTE LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Radioactive antibody could boost stem cell transplant success in tough leukemias
Disease control Recruiting nowThis study tests a radioactive antibody (211At-BC8-B10) given before a donor stem cell transplant for people with high-risk leukemias or related blood cancers. The antibody targets cancer cells and delivers radiation to help kill them while sparing healthy cells. The goal is to f…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 26, 2026 05:51 UTC
-
New hope for tough leukemias: targeted drug revumenib enters key trials
Disease control Recruiting nowThis study tests a new drug called revumenib in people with certain types of leukemia that have returned or not improved with standard treatments. The trial has two parts: first, finding the safest dose, then testing how well it works in four specific groups of patients. About 44…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Syndax Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 05:50 UTC
-
New cord blood transplant trial offers hope for tough blood cancers
Disease control Recruiting nowThis study tests a refined cord blood transplant method for people with hard-to-treat blood cancers like leukemia and lymphoma. Participants receive chemotherapy and radiation before the transplant to kill cancer cells and prepare the body, then donor stem cells are infused to re…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 26, 2026 05:50 UTC
-
New approach aims to stop Graft-Versus-Host disease in young cancer patients
Disease control Recruiting nowThis study tests whether removing a specific type of immune cell (naive T cells) from donated stem cells can prevent chronic graft-versus-host disease (GVHD) in children and young adults with blood cancers. GVHD occurs when donor cells attack the patient's body, causing long-term…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 26, 2026 05:49 UTC
-
New cell therapy aims to improve transplant outcomes for leukemia patients
Disease control Recruiting nowThis study tests a new treatment called Orca-T for people with acute myeloid leukemia or myelodysplastic syndrome. Orca-T is made from a donor's blood cells and is given after a gentle chemotherapy or radiation preparation. The goal is to see if it helps the body accept the trans…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE2 • Sponsor: Orca Biosystems, Inc. • Aim: Disease control
Last updated May 26, 2026 05:46 UTC
-
Gene therapy breakthrough targets Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-stage study tests a new gene therapy called VNX-101 for people with certain blood cancers (like leukemia and lymphoma) that have returned or not improved with standard treatments. The therapy uses a harmless virus to deliver a gene that helps the immune system attack c…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Vironexis Biotherapeutics Inc. • Aim: Disease control
Last updated May 26, 2026 05:46 UTC
-
Engineered donor cells aim to make stem cell transplants safer for blood cancer patients
Disease control Recruiting nowThis early-phase study is testing a new way to prepare donor stem cells, called Orca-Q, for people with certain blood cancers (like leukemia) who need a stem cell transplant. The goal is to see if this engineered graft is safe and helps the body accept the new cells without sever…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1 • Sponsor: Orca Biosystems, Inc. • Aim: Disease control
Last updated May 26, 2026 05:45 UTC
-
Could a targeted antibody boost leukemia survival in High-Risk kids?
Disease control Recruiting nowThis large phase 3 study is testing whether adding a targeted drug called inotuzumab ozogamicin to standard chemotherapy and immunotherapy can improve outcomes for children and young adults with high-risk B-cell acute lymphoblastic leukemia (B-ALL). The drug works like a guided m…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE3 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated May 26, 2026 05:42 UTC
-
New hope for kids with tough leukemia: targeted drugs added to chemo
Disease control Recruiting nowThis study tests whether adding either dasatinib or venetoclax to standard chemotherapy can help more children with T-cell acute lymphoblastic leukemia or lymphoma achieve a deep remission. About 100 children and young adults aged 1 to 18 will receive one of these targeted drugs …
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated May 26, 2026 05:40 UTC
-
New drug combo before transplant may stop blood cancer return
Disease control Recruiting nowThis study tests a new approach for adults with aggressive blood cancers (like AML) that are hard to treat. Patients get a stronger chemotherapy mix (decitabine plus FLAG-Ida) and total body radiation, followed by a donor stem cell transplant. The goal is to kill cancer cells and…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 26, 2026 05:40 UTC
-
New combo aims to boost leukemia treatment
Disease control Recruiting nowThis study tests adding venetoclax to a standard chemotherapy regimen (CLAG-M) for people with acute myeloid leukemia (AML) or related high-grade blood cancers. The goal is to find the safest dose and see if the combination improves cancer control. About 62 participants will be e…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
New drug duo targets tough leukemias in early trial
Disease control Recruiting nowThis study tests whether combining two drugs, revumenib and mezigdomide, is safe for people whose acute leukemia has returned or not responded to prior treatment. It includes adults and teens aged 12+ with specific genetic subtypes (KMT2A-r, NUP98-r, or NPM1-m). The first part fi…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
Immune cell boost may help young leukemia patients stay Cancer-Free after transplant
Disease control Recruiting nowThis study tests whether giving special immune cells (NK cells) before and after a stem cell transplant can help prevent leukemia from coming back in children and young adults (ages 0–25) with hard-to-treat acute leukemia. The NK cells are grown in a lab and come from the same do…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE2 • Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
New stem cell transplant study offers hope for blood cancer patients
Disease control Recruiting nowThis study tests a stem cell transplant from a half-matched donor for people with blood cancers. Before the transplant, patients receive chemotherapy and low-dose radiation to prepare the body. The goal is to see if this approach helps the new stem cells grow and fight cancer wit…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
New cell therapy aims to make mismatched donor transplants safer for blood cancer patients
Disease control Recruiting nowThis early-stage trial tests a cell therapy called Orca-T combined with standard drugs to prevent graft-versus-host disease (GVHD) in up to 24 adults with advanced blood cancers like leukemia or MDS. Participants receive a stem cell transplant from a donor who is only a 7 out of …
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1 • Sponsor: Stanford University • Aim: Disease control
Last updated May 20, 2026 11:57 UTC
-
New pill for tough leukemias enters early human testing
Disease control Recruiting nowThis early-phase trial is testing an experimental oral drug, MRX-2843, in adolescents and adults whose acute leukemia has returned or not responded to standard treatments. The main goals are to check the drug's safety and find the best dose. About 50 participants will take the dr…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1 • Sponsor: Meryx, Inc. • Aim: Disease control
Last updated May 19, 2026 11:47 UTC
-
New hope for babies with aggressive leukemia: targeted therapy trial launches
Disease control Recruiting nowThis study tests a drug called blinatumomab in infants under 1 year old who have a specific, hard-to-treat type of leukemia (KMT2A-rearranged). The goal is to improve how long these babies stay cancer-free and to help them live longer. About 160 infants will take part, and the tr…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE3 • Sponsor: Princess Maxima Center for Pediatric Oncology • Aim: Disease control
Last updated May 18, 2026 12:12 UTC
-
Engineered immune cells take aim at returning leukemia
Disease control Recruiting nowThis early-phase trial tests a new treatment for children and adults with acute leukemia that has come back or not responded after a donor stem cell transplant. The treatment uses specially engineered immune cells (T cells) from the original donor that are trained to recognize an…
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 18, 2026 12:03 UTC
-
New study gives kids with leukemia a head start on tailored treatment
Knowledge-focused Recruiting nowThis study enrolls children aged 1 to 18 with newly diagnosed acute lymphoblastic leukemia, lymphoblastic lymphoma, or mixed phenotype acute leukemia. The main goal is to give enough initial treatment while doctors gather genetic and lab information to decide the best risk-based …
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE4 • Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated May 26, 2026 05:45 UTC
-
New hope for kids with tough leukemias: screening trial matches patients to targeted therapies
Knowledge-focused Recruiting nowThis study screens children and young adults (under 22) with leukemia that has returned or is difficult to treat. By analyzing their blood and bone marrow, doctors can identify specific genetic markers to match them with the most promising experimental treatments. The goal is to …
Matched conditions: MIXED PHENOTYPE ACUTE LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: PedAL BCU, LLC • Aim: Knowledge-focused
Last updated May 22, 2026 13:54 UTC